{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T21:44:49Z","timestamp":1772833489508,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.anai.2021.01.015","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T01:55:28Z","timestamp":1610934928000},"page":"666-673","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["No difference in omalizumab efficacy in patients with asthma by number of asthma-related and allergic comorbidities"],"prefix":"10.1016","volume":"126","author":[{"given":"Meng","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Choo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bongin","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranil","family":"Raut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tmirah","family":"Haselkorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hooman","family":"Pazwash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecile T.J.","family":"Holweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Golda","family":"Hudes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.anai.2021.01.015_bib1","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/all.13370","article-title":"Comorbid \u201ctreatable traits\u201d in difficult asthma: current evidence and clinical evaluation","volume":"73","author":"Tay","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2021.01.015_bib2","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12887-015-0481-x","article-title":"Characteristics and severity of asthma in children with and without atopic conditions: a cross-sectional study","volume":"15","author":"Arabkhazaeli","year":"2015","journal-title":"BMC Pediatr"},{"issue":"9","key":"10.1016\/j.anai.2021.01.015_bib3","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ppul.23443","article-title":"Co-morbidities and cognitive status in a cohort of teenagers with asthma","volume":"51","author":"Cohen","year":"2016","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.anai.2021.01.015_bib4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jaip.2017.06.008","article-title":"Comorbidities in difficult-to-control asthma","volume":"6","author":"Hekking","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2021.01.015_bib5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/02770903.2017.1316394","article-title":"Asthma control and disease burden in patients with asthma and allergic comorbidities","volume":"55","author":"Lee","year":"2018","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.anai.2021.01.015_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.rmed.2018.01.020","article-title":"Comorbidity, disease burden and mortality across age groups in a Swedish primary care asthma population: an epidemiological register study (PACEHR)","volume":"136","author":"Lisspers","year":"2018","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.anai.2021.01.015_bib7","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1159\/000439310","article-title":"Different severity and severity predictors in early-onset and late-onset asthma: a Taiwanese population-based study","volume":"90","author":"Wu","year":"2015","journal-title":"Respiration"},{"key":"10.1016\/j.anai.2021.01.015_bib8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2466-13-46","article-title":"Major comorbid conditions in asthma and association with asthma-related hospitalizations and emergency department admissions in adults: results from the German National Health Telephone Interview Survey (GEDA) 2010","volume":"13","author":"Steppuhn","year":"2013","journal-title":"BMC Pulm Med"},{"issue":"3","key":"10.1016\/j.anai.2021.01.015_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020825","article-title":"Risk factors of asthma exacerbation based on asthma severity: a nationwide population-based observational study in South Korea","volume":"8","author":"Kang","year":"2018","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.anai.2021.01.015_bib10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jaci.2016.12.940","article-title":"Mechanisms of the Development of Allergy (MeDALL): introducing novel concepts in allergy phenotypes","volume":"139","author":"Anto","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2021.01.015_bib11","first-page":"CD003559","article-title":"Omalizumab for asthma in adults and children","volume":"1","author":"Normansell","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.anai.2021.01.015_bib12","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jaip.2017.02.002","article-title":"\u201cReal-life\u201d effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis","volume":"5","author":"Alhossan","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2021.01.015_bib13","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2021.01.015_bib14","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Sol\u00e8r","year":"2001","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.anai.2021.01.015_bib15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"issue":"9","key":"10.1016\/j.anai.2021.01.015_bib16","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.anai.2021.01.015_bib17","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study","volume":"7","author":"Casale","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2021.01.015_bib18","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.anai.2017.09.056","article-title":"Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO","volume":"119","author":"Chipps","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"10.1016\/j.anai.2021.01.015_bib19","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2021.01.015_bib20","series-title":"Xolair [Prescribing Information]","year":"2019"},{"issue":"4","key":"10.1016\/j.anai.2021.01.015_bib21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000498861","article-title":"Multimorbidity in asthma, allergic conditions and COPD increase disease severity, drug use and costs: the Finnish pharmacy survey","volume":"179","author":"Jantunen","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"issue":"1","key":"10.1016\/j.anai.2021.01.015_bib22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pupt.2014.01.007","article-title":"Omalizumab management beyond clinical trials: the added value of a network model","volume":"29","author":"Caminati","year":"2014","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.anai.2021.01.015_bib23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaci.2017.11.051","article-title":"Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma","volume":"142","author":"Weinstein","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2021.01.015_bib24","doi-asserted-by":"crossref","first-page":"AB12","DOI":"10.1016\/j.jaci.2017.12.038","article-title":"Clinical efficacy of benralizumab in patients with severe, uncontrolled eosinophilic asthma and nasal polyposis: pooled analysis of the SIROCCO and CALIMA trials","volume":"141","author":"Maspero","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2021.01.015_bib25","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaip.2018.08.021","article-title":"Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps","volume":"7","author":"Weinstein","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2021.01.015_bib26","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.jaip.2020.01.019","article-title":"Determinants of lung function improvement with omalizumab in adults with allergic asthma","volume":"8","author":"Hanania","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2021.01.015_bib27","doi-asserted-by":"crossref","unstructured":"Casale TB, Chipps B, Haselkorn T, et\u00a0al. Effect of reversibility and eosinophils on lung function improvement with omalizumab treatment: pooled analyses in patients with moderate or severe allergic asthma. Presented at: American Thoracic Society International Conference; May 17-22, 2019; Dallas, TX.","DOI":"10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A1270"},{"key":"10.1016\/j.anai.2021.01.015_bib28","doi-asserted-by":"crossref","unstructured":"Hanania NA, Haselkorn T, Ortiz B, Yoo B, Holweg CT, Chipps B. Response to omalizumab in patients with fixed airflow obstruction. Presented at: CHEST Annual Meeting; October 19-23, 2019; New Orleans, LA.","DOI":"10.1016\/j.chest.2019.08.869"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120621000235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120621000235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:26:43Z","timestamp":1761053203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120621000235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1081120621000235"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2021.01.015","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No difference in omalizumab efficacy in patients with asthma by number of asthma-related and allergic comorbidities","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2021.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American College of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}